Business Context and Reporting Period
This Form 8-K Current Report was filed by Bristol-Myers Squibb Company on December 17, 2009, regarding events occurring on December 14, 2009. The filing addresses significant changes in the company's executive leadership, specifically within the finance organization.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure: Jean-Marc Huet, Executive Vice President and Chief Financial Officer, will resign effective December 31, 2009.
- Appointment: Charles A. Bancroft will be appointed as Acting Chief Financial Officer effective January 1, 2010.
- Leadership Role: Mr. Bancroft will join the Management Council, the company's senior-most leadership team.
Management Commentary and Compensation
Mr. Bancroft, a 25-year employee, has held increasing responsibility within the finance organization, including international assignments and senior leadership in the global pharmaceutical business. His most recent role prior to this appointment was Vice President, Finance for the worldwide pharmaceuticals group since October 2005.
Effective January 1, 2010, Mr. Bancroft's compensation package includes:
- Annual base salary of $500,000.
- Target bonus opportunity of 80% of base salary under the Senior Executive Performance Incentive Plan.
- Participation in the standard annual long-term incentive award program (restricted stock units and performance shares).
- Change-in-control benefits consistent with other Named Executive Officers.
The filing states there are no related party transactions or special understandings regarding Mr. Bancroft's selection.
Investor Verification Checklist
- Verify the exact effective dates for Mr. Huet's resignation and Mr. Bancroft's appointment.
- Review the attached press release (Exhibit 99.1) for additional context on the leadership transition.
- Confirm Mr. Bancroft's tenure and specific prior roles within the finance organization.
- Check subsequent filings for the appointment of a permanent Chief Financial Officer following the "Acting" period.